RTP Mobile Logo
Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer (Faculty Presentations)
Released July 2020

Featuring slide presentations and related discussion with Drs Robert L Coleman, Stephanie Lheureux, Joyce F Liu and Kathleen Moore. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

    Epithelial ovarian cancer (OC) accounts for approximately 90% of malignant ovarian neoplasms, and this makes it the leading cause of death from gynecologic cancer in the United States. The most significant recent development in OC has been the introduction of PARP inhibitors into the therapeutic milieu, and important advances in the collective understanding of PARP inhibition as a mechanism to impede the development and progression of OC have led to FDA approval of multiple agents in a number of clinical settings. The availability of PARP inhibitors has significant ramifications for practicing oncologists, who need to confront a variety of practical issues with regard to the safe and effective use of these new drugs.

    These video presentations captured in conjunction with a virtual satellite symposium originally planned to be held live at the 2020 SGO meeting in Toronto features discussions with leading OC researchers regarding actual cases from their practices, related survey results and the published data that drive clinical decision-making for patients in those and diverse other situations. By providing information on the latest research and its potential application in routine practice, this activity is designed to assist medical oncologists, gynecologic oncologists and other healthcare providers with the formulation of up-to-date clinical management strategies.


    • Understand the biology of PARP inhibition and consider recommended guidelines for genetic testing that inform treatment decision-making for patients with OC.
    • Recognize the FDA approvals of olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC harboring a deleterious or suspected deleterious BRCA germline or somatic mutation, and in combination with bevacizumab as first-line maintenance therapy for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are experiencing complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency, and appropriately integrate these approaches into current care algorithms.
    • Recognize the recent FDA approval of niraparib as maintenance therapy in the first-line setting for patients with advanced epithelial OC with or without BRCA mutations, and consider the clinical and research implications of these findings.
    • Appreciate the biologic rationale for and available data with the use of PARP inhibitors in combination with chemotherapy, and discern how these therapeutic approaches may affect treatment algorithms in the future.
    • Assess available clinical trial data with and approved indications for the use of FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC in order to design personalized care plans potentially incorporating these agents.
    • Recognize the toxicities associated with PARP inhibitors commonly used for OC, and offer supportive management strategies to minimize or ameliorate these side effects.
    • Develop an understanding of the rationale for, available data with and ongoing research evaluating PARP inhibitors in combination with immunotherapy or other targeted therapies in order to counsel appropriately selected patients about clinical trial participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Robert L Coleman, MD
    Chief Scientific Officer
    US Oncology Research
    Gynecologic Oncology
    The Woodlands, Texas

    Advisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Janssen Biotech Inc, Merck, Novocure, Roche Laboratories Inc, Takeda Oncology, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, VBL Therapeutics.

    Stephanie Lheureux, MD, PhD
    Clinician Investigator
    Drug Development Program - Gynecology
    Division of Medical Oncology and Hematology
    Gynecology Site Lead
    Princess Margaret Cancer Centre
    Assistant Professor
    University of Toronto
    Toronto, Canada

    Advisory Committee: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, Roche Laboratories Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline; Contracted Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc.

    Joyce F Liu, MD, MPH
    Assistant Professor of Medicine
    Harvard Medical School
    Director of Clinical Research, Division of Gynecologic Oncology
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, Merck, Regeneron Pharmaceuticals Inc, Tesaro, A GSK Company; Contracted Research: Agenus Inc, Aravive Inc, Arch Oncology, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, CytomX Therapeutics, Genentech, a member of the Roche Group, Oncology Venture A/S, Regeneron Pharmaceuticals Inc, Surface Oncology, Tesaro, A GSK Company, Vigeo Therapeutics.

    Kathleen Moore, MD
    The Virginia Kerley Cade Endowed Chair in Cancer Development
    Associate Director, Clinical Research
    Director, Oklahoma TSET Phase I Program
    Stephenson Cancer Center
    Associate Professor, Section of Gynecologic Oncology
    Director, Gynecologic Oncology Fellowship
    Department of Obstetrics and Gynecology
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma

    Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Aravive Inc, Clovis Oncology, Eisai Inc, Genentech, GlaxoSmithKline, ImmunoGen Inc, Merck, Mereo BioPharma, Tarveda Therapeutics, Tesaro, A GSK Company, Vavotar Life Sciences; Contracted Research: Clovis Oncology, Genentech, Merck, PTC Therapeutics; Employment: GOG Foundation/Partners.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Merck and Tesaro, A GSK Company.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: July 2020
    Expiration date: July 2021

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):